Application of Nanomaterials in the Field of Medicine – Medical News Bulletin

There has been a growing interest in the different applications of nanomaterials in the field of medicine. An article published in Nanomedicine: Nanotechnology, Biology, and Medicine showed the ways in which Laponite, a synthetic clay made of nanomaterials, can be of use in clinical practice.

Current advances in technology have provided many opportunities to develop new devices that improve the practice of medicine. There has been a growing interest in the different applications of nanomaterials in the field of medicine.

An article published in Nanomedicine: Nanotechnology, Biology, and Medicine reviewed Laponite, a non-toxic synthetic clay composed of nanomaterials which has different uses in the field of medicine. Laponite can be used in drug delivery systems, as the synthetic clay protects substances from degradation in physiologic environments. Different experiments show that Laponite is effective not only in protecting drugs from degradation, but also in transporting and releasing drugs into the body. The degradation of Laponite in the physiologic environment also releases products which have biological roles, especially in bone formation.

Laponite has been shown to induce osteogenic differentiation of cells in the absence of other factors which are known to promote differentiation and cell growth. The application of nanomaterials in bioimaging has also been studied. In one experiment, Laponite was incorporated with gadolinum, a dye used in magnetic resonance imaging (MRI), resulting in brighter images and prolonged contrast enhancement for 1 hour post-injection. Laponite has also proven to be of use in the field of regenerative medicine and tissue engineering. This synthetic clay can elicit specific biologic responses, act as a carrier for biochemical factors, and improve the mechanical properties of scaffolds used for tissue growth.

In summary, nanomaterials and synthetic clays such as Laponite have many applications in the field of medicine. Although current published literature state no toxic effects on the human body, further studies are needed to assess safety before it can be applied to clinical practice.

Written By:Karla Sevilla

Add to Flipboard Magazine.

The rest is here:

Application of Nanomaterials in the Field of Medicine - Medical News Bulletin

Nanomedicine and Extracellular Vesicles Lab – Kokomo Perspective

BOURBONNAIS, Ill. What is the biggest difference in the 2017 Chicago Bears since we left them at 3-13 last January?

Over the last six months, it has become crystal clear to anyone paying close attention the Chicago Bears are now general manager Ryan Paces team, while head coach John Fox just works there.

In the past two-and-a-half years, we can count on one hand the number of times Pace has spoken publicly without Fox by his side, and until last January it was always Fox who dominated those occasions, at times feeling the need to add to Paces comments and even finish answers for him.

Meeting with Pace and Fox Wednesday at the opening of the Bears' 2017 training camp, it was clearly Ryan Paces show, completing the turnaround in control hes been asserting this offseason.

For anyone keeping score, after each gave a brief opening statement, the first 12 questions were all directed at Pace with Fox only weighing in on two of them because Pace asked him to, and many of them were about how Pace was handling the quarterback position, playing time and other decisions often left to the head coach.

Asked how he will measure the progress of this years Bears, Pace replied, I know that the culture and the vibe of the locker room is really good right now.

When we talk about playing with toughness and intelligence and passion and all those traits we strive for, I feel like weve got a team that embodies those traits.

Asked about the pressure on Fox to perform well enough to keep his job entering the third year of his four-year deal, Pace was careful to accept some of the pressure to win on himself while acknowledging it is time to win more, and he also offered a second measuring stick through which Fox will be evaluated.

I hear theres pressure on this theres pressure on all of us. Theres a lot of pressure on me, and we all know what we signed up for," he said. "I think the focus now is winning games, but if theres one thing I can stress with John and things I appreciate every day its look, its very difficult to change a culture.

John is doing that and he has done that while also getting younger as a team. And doing that together has been difficult, and I appreciate that with him.

Asked how Fox is changing the culture, Pace explained, I think you guys know when you can feel a team that has come together, you can feel the locker room.

"Guys, this is just the very beginning, but you just feel a lot of good teammates. A lot of unselfish, team-first type of players, which I think is really important.

I think weve all seen good teams ascend, and I think it starts with the quality of the character in the locker room, and I think we have good character in our locker room.

How much pressure is on Fox to win now ultimately remains unclear, but Pace did acknowledge the ultimate judgments come from the McCaskeys ownership perch and he did talk about what he believes they expect.

That conversation is always ongoing. I just think they want to see continued improvement," he said. "I think they know theres no quick fix. We talked about that. Its about building this team the right way, with the right kind of guys. And weve just got to show progress.

I think as we go forward, our fans are going to see a tough, blue collar, grind-it-out kind of team thats on the ascension and its something they can be part of.

I suspect Pace is right about how he will be evaluated and that he remains very safe in the eyes of the McCaskeys.

But while the culture may be improving, 2016 was a regression from six wins to three rather than progress, and whether Fox can expect that same leeway as Pace remains a serious question as practices begin Thursday.

See the rest here:

Nanomedicine and Extracellular Vesicles Lab - Kokomo Perspective

International Conference and Exhibition on Nanomedicine and Nanotechnology – Technology Networks

Short Name: Nanomed Meeting 2017

Theme: Challenges and Innovations in next generation medicine

Website: http://www.meetingsint.com/pharma-conferences/nanomedicine-nanotechnology

Registration Link: http://www.meetingsint.com/pharma-conferences/nanomedicine-nanotechnology/registration

Nanomed Meeting 2017 Organizing Committee invites you to attend the largest assemblage of Nanomedicine and Nanotechnology researchers from around the globe during November 23-24, 2017 at Dubai, UAE.

Nanomed Meeting 2017 is a global annual event. This International Conference and Exhibition on Nanomedicine and Nanotechnology brings together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. The passage of Nanomed Meeting 2017 through a decade at Asia finds much requirement for discussion also focusing the latest developments in the field of Nanomedicine and Nanotechnology.

Why attend?

Join your peers around the world focused on learning about Nanomedicine and Nanotechnology related advances, which is your single best opportunity to reach the largest assemblage of participants from the Nanomedicine and Nanotechnology community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with a new research works, and receive name recognition at this 2-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Nanomedicine and Nanotechnology are hallmarks of this conference.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

The rest is here:

International Conference and Exhibition on Nanomedicine and Nanotechnology - Technology Networks

Global Nanomedicine Market 2017-2022 – Hoffmann-La Roche Ltd … – DailyHover

Worldwide Nanomedicine Market 2017 provides the in-depth research study shedding lights on different business verticals, key business factors which lead to market development, services offered by Nanomedicine industry. Worldwide Nanomedicine report is segmented into different categories based on the manufacturing regions to provide complete knowledge of Nanomedicine industry which will help them in making vital decisions. The opportunities, threats, and business strategies are covered in this report, forecast from 2016-2022.

Market Insights:

The consistent global demand for Nanomedicine provide positive growth opportunities for Nanomedicine market.The report identified that the global Nanomedicine market is driven by factors such as massive growth in Healthcare industry and commercial application in Healthcare industry. The growing demand from Healthcare industries are expected to drive the global Nanomedicine market. The growth in the Global Nanomedicine Market is likely to be restrained by factors such as High investment costs and longer duration of implementation.The global Nanomedicine market is expected to exhibit a CAGR of 17.1 % during the assessment period from 2016-2022.

Before purchasing the report please do inquire here: https://market.biz/report/global-nanomedicine-market-2017-ihr/103194/#inquiry

Initially, Worldwide Nanomedicine report provides basic industry overview to the reader. Then the key aspects of the Nanomedicine industry showing the growth of the market, product definitions, applications, Nanomedicine market scope on a global scale have been mentioned in this report. The research methods followed to gather all the Nanomedicine industry details has been included in this report.

The dominant Nanomedicine industry players are as follows:

1) Merck & Co.Inc. 2) Hoffmann-La Roche Ltd. 3) Gilead Sciences Inc. 4) Novartis AG 5) Amgen Inc. 6) Pfizer Inc. 7) Eli Lilly and Company 8) Sanofi 9) Nanobiotix SA 10) UCB SA

Worldwide Nanomedicine market than does the analysis of the dominant market players based on their company profiles, sales margin, customer volume, demand and supply ratio, business tricks followed by them. All the existing and emerging market segments of Nanomedicine market has been covered in this research report. The product price, market constraints, and evolving market regions have been included in this report.

The Geographical Analysis of Nanomedicine market:

1. Latin America (The Middle East and Africa)

2. Europe (UK, Germany, France, Italy, and Russia)

3. Asia-Pacific (India, China, Korea, Japan and Southeast Asia)

4. North America (The USA, Canada, and Mexico)

The SWOT analysis of the Nanomedicine market, business trends, geographic revenue, business sections has been included in this report.

Towards the end, important research findings, product releases, collaborations have been incorporated in Nanomedicine research report.

More here:

Global Nanomedicine Market 2017-2022 - Hoffmann-La Roche Ltd ... - DailyHover

Tiny robots swim the front crawl through your veins – New Scientist

Michael Phelps: Faster than a nano-swimmer but wont fit in your veins

Francois Xavier Marit/AFP/Getty Images

By Leah Crane

Its no Michael Phelps, but this tiny magnetic robot swims the front crawl at 10 micrometres per second. It would take about two months for the bot to swim the length of an Olympic swimming pool in that time, Phelps could swim almost 5 million lengths. But the nano-swimmer is fast for its size, and its strong enough to pass through more viscous liquids, like blood, to deliver medicine from inside your veins.

The front crawl is the fastest way for humans to swim. So Tianlong Li at the Harbin Institute of Technology in China and his colleagues built their swimming robot to mimic that motion.

Each nano-swimmer is 5 micrometres long and has three main parts, connected together like sausage links by two silver hinges. Its gold body is flanked by two magnetic arms made of nickel, and applying a magnetic field to the tiny robot makes the arms move.

As the researchers switch the magnetic fields direction back and forth, it causes the arms of the nano-swimmer to rotate and propel it forward, just like the arms of a human swimmer doing the front crawl.

Its exciting due to its speed and its really small size, just about the same size as a blood vessel, says Eric Diller at the University of Toronto in Canada who researches micro-robots. Its small enough basically to go anywhere within the body.

Because bodily fluids are more viscous and difficult to swim through than water, the researchers also tested their nano-swimmers in serum. The bots were only able to swim 5.5 micrometres per second, but thats still faster than many other similar mini-machines.

For targeted medicine delivery without invasive procedures, these nano-swimmers could be coated with medicine and injected into the bloodstream, where their trajectories could be roughly steered by external magnetic fields.

Since they are so small, just one nano-swimmer wouldnt be able to carry enough medicine to actually help. Maybe a thousand of them would be necessary, says Diller. Theres no way to keep track of all of them, so there are a lot of questions about safety and toxicity.

The next generation of these tiny machines will have to be made from biodegradable materials before they can be used in the bloodstream. But, Diller says that for less complicated areas in the human body like the urinary tract or the eyeballs, clinical trials could begin within the next five to 10 years. Injecting a single swimmer into an eyeball, where it could deliver medication directly to the retina and then be removed, would be much less complicated than letting a swarm of them swim throughout the entire circulatory system.

We dont know how fast Michael Phelps could swim through blood thankfully, his recent race against a great white shark didnt provide a testing ground. But since you cant inject him into your bloodstream, these nano-swimmers will have to do.

Journal reference: Nano Letters, DOI: 10.1021/acs.nanolett.7b02383

Read more: DNA origami nanorobot takes drug direct to cancer cell

More on these topics:

Read more:

Tiny robots swim the front crawl through your veins - New Scientist

Chennai firm to produce ayurvedic drugs for cancer thru nanotech – Hindu Business Line

Chennai, July 21:

Chennai-based Dhanvantari Nano Ayushadi Pvt Ltd will produce nano ayurvedic medicine to treat cancer using green nanotechnology. The products are expected to hit the shelves in early 2018 after clinical trial.

Green nanotechnology uses herbs and spices such as cinnamon, tea or soyabean to synthesise gold nanoparticles. The activated gold nano particles are then used to make capsules and tablets that can be consumed. The technology is developed by Kattesh V Katti, Director, Institute of Green Nanotechnology, Medical School, University of Missouri in the US.

Addressing the media today, S Abhaya Kumar, Chairman, Nano Ayushadi, said clinical trials will start from August 1 under the guidelines issued by the Union Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy (AYUSH). Trials will be conducted over a period of 3-6 months on 100 people selected through random sampling. The company has invested 60 crore to license the technology, manufacturing unit and clinical trial. With scientific backing, we expect to sell close to 20 million capsules initially, he added. In the next five years, we expect to be a 1,000-crore company, he added.

The company is in talks with cancer institutes, hospitals and doctors to reach a wider audience. Kumar said products would be available through Ayurveda distributors and e-commerce platforms.

Talking about the effectiveness of the product, Katti , said that from the trials conducted on over 100 animals over a period of four years, nano ayurvedic medicine is found to reduce the tumour without side effects. When the medicine is taken alongside chemotherapy, it has shown to be effective, he added.

(This article was published on July 21, 2017)

Please enter your email. Thank You.

Newsletter has been successfully subscribed.

Link:

Chennai firm to produce ayurvedic drugs for cancer thru nanotech - Hindu Business Line

Paras Prasad receives honorary doctorate in Brazil – UB News Center

BUFFALO, N.Y. University at Buffalo researcher Paras Prasad, an internationally recognized expert in optics and photonics, has been awarded an honorary doctorate from the Federal University of Pernambuco (UFPE) in Brazil.

Prasad, PhD, who serves as the executive director of UBs Institute for Lasers, Photonics and Biophotonics (ILPB), received the award on July 6.

The honor stems from a 19-year ongoing partnership that Prasad a SUNY Distinguished Professor in UBs departments of chemistry, physics, medicine and electrical engineering formed with the Brazilian university.

Since 1999, Prasad has co-authored 19 scientific papers and received grants with UFPE collaborators, given numerous lectures and helped organized conferences at the Brazilian university, hosted UFPE students at UB, and connected UFPE researchers with counterparts in China, France and elsewhere.

Working with UFPE has been one of the most gratifying experiences in my career, said Prasad, who was an early pioneer in nanomedicine, which uses super-small particles, materials and devices to treat and diagnose disease. I am humbled to receive such an honor.

Prasad specializes in the use of optics, photonics and nanotechnology in this field, and has worked with colleagues to study and develop a wide range of new materials that could ultimately improve lives around the world.

These novel materials include miniature luminescent crystals that could be used in image-guided surgery; light-activated nanoparticles that could enable the development of new bioimaging technologies for disease detection; new nanoneurotechnologies for monitoring and enhancing brain functions; and magnetic and laser-activated nanoparticles that could be used for cancer diagnosis and treatment. This latter technology was licensed to UB spinoff Nanobiotix, a publicly traded company and leader in nanomedicine that has maintained close contact with Prasad while working to develop these and other new nanomedicine products.

Prasad has published more than 750 scientific papers, eight edited books and four monographs, and has been named the inventor or co-inventor on numerous patents. In keeping with his emphasis on the translational impact of his research, Prasad has been extremely active in launching startup companies and partnering with industry for co-development of technologies to create new companies. His efforts have led to 9 different companies worldwide.

He has received numerous regional, national and international recognitions for his lifetime achievements, including the Morley Medal; Jacob F. Schoellkopf Medal; Guggenheim Fellowship; Sloan Fellowship; Western New York Health Care Industries Technology/Discovery Award; and Excellence in Pursuit of Knowledge Award of the Research Foundation for SUNY. He was named a fellow of the American Physical Society, OSA (the Optical Society) and SPIE (the international society for optics and photonics).

The SPIE awarded Prasad its highest honor: the Gold Medal. The University at Buffalo awarded him the high honor of the UB Presidents Medal in 2016 in recognition of extraordinary service to the university, and he also received UBs inaugural Innovation Impact Award in 2015 for his contributions to the invention of the technologies licensed to Nanobiotix.

In 2005, he was named one of the Scientific American 50, the magazines list of visionaries from the worlds of research, industry and politics whose recent accomplishments point toward a brighter technological future for everyone. He was on the Thomson Reuters Highly Cited Researchers list for 2014 and 2016.

Prasad has received honorary doctorates from KTH Royal Institute of Technology in Sweden; the Aix-Marseille University in France; and the National Research Nuclear University (MEPhI) in Russia.

Read more:

Paras Prasad receives honorary doctorate in Brazil - UB News Center

Indestructible virus yields secret to creating incredibly durable … – Phys.Org

July 19, 2017 Peter M. Kasson, M.D., Ph.D., (left) and Edward H. Egelman, Ph.D., have unlocked the secrets of a nearly indestructible virus, potentially allowing scientists to harness its remarkable properties to create super-durable materials and better treat disease. Credit: Josh Barney, UVA Health System

It's like the Superman of viruses, astonishingly tough and able to survive in an environment that would dissolve flesh and bone. And now scientists have unlocked the secrets of its indestructibility, potentially allowing them to harness its remarkable properties to create super-durable materials and better treat disease.

The discovery reveals something never before seen in the natural world. Potential uses include everything from pinpoint delivery of cancer drugs so they only attack tumors to building materials that could better withstand an earthquake's tremors.

"Anytime you find something that behaves really differently, especially something this stable, it's interesting and potentially useful," said researcher Peter M. Kasson, MD, PhD, of the University of Virginia School of Medicine. "When you're doing curiosity-driven science that finds something new, in the back of your mind, you think, 'Hey, this is really different. What might it be good for?' And this has many potential applications."

Advancing Nanomedicine

The virus, Acidianus hospitalis Filamentous Virus 1, lives in hot springs in Yellowstone National Park - bubbling pools of acid in which the temperature often exceeds 175 degrees. The virus was first isolated in 2002 by David Prangishvili from the Pasteur Institute and his colleagues. Now, the UVA researchers have determined it is protected by a type of membrane science has never before encountered. Its outer coat is half as thick as known cell membranes, yet it is amazingly stable. That's because of the unusual, horseshoe-shaped arrangement of its membrane molecules, providing a small size yet remarkable durability that scientists might duplicate for many other purposes. For example, it may offer a way to make microscopic particles of medicine shelf stable, so that they don't need refrigeration.

One of the most likely applications is in the field of nanomedicine, which might use the discovery to create super-strong wrappers for molecules of drugs so that they can be delivered exactly where they're needed. For example, directly to a cancer tumor. The durable wrappers would withstand the body's best efforts to degrade the foreign substance.

The video will load shortly

"There are all sorts of potential applications in material science, building things, medicine," said researcher Edward H. Egelman, PhD, of UVA's Department of Biochemistry and Molecular Genetics. "We can use natural products, cellular proteins, etcetera to design many new things that are useful. Wool, essentially, is hair, and that's used extensively to make fabrics. That's a protein. So there are many implications for using this to build new materials."

He noted that Teflon is a good example of similarly repurposed science. "Teflon was not invented as a way to make non-stick cookware," he said. "It was found by chemists on accident, but it proved very useful."

Cool Science

To unlock the secrets of the indestructible virus, Egelman used the power of UVA's mighty Titan Krios electron microscope, a microscope so sensitive it had to be buried underground to protect it from the slightest vibration. Kasson then used advanced computer modeling to determine the strange shape of the lipid membrane molecules. "Essentially, we encode everything we know about the physics of these molecules and then come up with models that are both consistent with the basic physics and consistent with the observations from the electron microscope," explained Kasson, of UVA's Department of Molecular Physiology and Biological Physics.

Egelman and Kasson were surprised by what they found, something so unusual and so potentially useful. "It's amazing how much we still don't know about life as it exists on Earth - at the bottom of the ocean, in the deep sea vents, or places like Yellowstone or Iceland where you have these very strange environments we think of as inhospitable to life," Egelman said. "But the things that live there, they may look at our environment and think, 'Strange.'"

Findings Published

The researchers have published their discovery in the scientific journal eLIFE. The team consisted of Egelman, Kasson, Frank DiMaio, Xiong Yu, Soizick Lucas-Staat, Mart Krupovic, Stefan Schouten and Prangishvili.

Explore further: Nearly indestructible virus yields tool to treat diseases

More information: Peter Kasson et al, Model for a novel membrane envelope in a filamentous hyperthermophilic virus, eLife (2017). DOI: 10.7554/eLife.26268

Journal reference: eLife

Provided by: University of Virginia

By unlocking the secrets of a bizarre virus that survives in nearly boiling acid, scientists at the University of Virginia School of Medicine have found a blueprint for battling human disease using DNA clad in near-indestructible ...

A hugely destructive plant virus so flexible that it has resisted efforts to describe its form since before World War II has finally surrendered its secrets. The discovery of what makes the bendy bug so malleable will revolutionize ...

(Medical Xpress)Researchers at the University of Virginia School of Medicine have discovered how the deadly Ebola virus punches its way into the cytoplasm of cells. The finding identifies an important target for blocking ...

To establish an infection in the urinary tract, bacteria must be able to withstand the tremendous forces of urine flow so they're not simply washed away. New research is giving scientists a remarkable view of a strange, spring-like ...

Drugs disguised as viruses are providing new weapons in the battle against cancer, promising greater accuracy and fewer side effects than chemotherapy.

Researchers at Karolinska Institutet, Sweden, have developed a nanoparticle technology that can be used to stabilise membrane proteins so that their structure can be studied in a lipid environment. The method, described in ...

(Phys.org)When most people hear the term "CO2 emissions," they probably think of several negative things: greenhouse gas, pollutant, climate change, political discord, economic burden. But a team of researchers led by ...

A boosting skin vaccination with a biodegradable microneedle patch and protein constructed from sequences of influenza virus subtypes could improve the effectiveness of conventional influenza vaccines, according to a study ...

Using the principles of light, University of Leeds scientists have discovered a new way to measure the strength of modern forms of concrete - giving industry a better way to understand when it could fracture.

Catheters, intravenous lines, and other types of surgical tubing are a medical necessity for managing a wide range of diseases. But a patient's experience with such devices is rarely a comfortable one.

Nitrogen is abundantly available in nature and forms the basis for many valuable products, both natural and artificial. This requires a reaction known as "nitrogen fixation", whereby molecular nitrogen is split into two atoms ...

Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers. The tiny capsules, which are invisible to the naked eye, can protect sensitive molecular materials, and could prove a ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read this article:

Indestructible virus yields secret to creating incredibly durable ... - Phys.Org

6th Round of applications for the NanomedTAB is open – Cordis News

The Nanomedicine Translation Advisory Board (nanomedTAB) offers since 2015 a free-of-charge mentoring program to assess, advise and accelerate promising nanomedicine projects to the market, based on a team of top skills industry experts with diverse and complementary experience. The objective? Help all projects and teams to get to clinical and commercial application faster and more reliably.

The deadline for applications is 18 September 2017.

- 71 teams have already applied; - from 16 countries in EU and beyond; - more than 50% have been selected and are now benefiting from coaching over time.

Selected projects will be invited to attend the next TAB-In Sessions, a series of face to face meetings with experts to be held on October 19th, 2017 in Malaga (Spain), in the framework of the 12th ETP Nanomedicine Annual Event.

Applications should be submitted through the following link: http://www.nanomedtab.eu/?apply. Further information about the nanomedTAB and its experts can be found at http://www.nanomedtab.eu.

Read more:

6th Round of applications for the NanomedTAB is open - Cordis News

University of Missouri research institute closes amid cuts – Lexington Herald Leader

University of Missouri research institute closes amid cuts
Lexington Herald Leader
University spokesman Christian Basi tells the Columbia Missourian (http://bit.ly/2vxVf4L ) that the decision to close the International Institute of Nano and Molecular Medicine will affect 17 full-time and part-time employees through layoffs and ...

and more »

More:

University of Missouri research institute closes amid cuts - Lexington Herald Leader

Nanomedicine Opens Door to Precision Medicine for Brain Tumors – Northwestern University NewsCenter

The new therapeutic strategy involves injecting lipid polymer-based nanoparticles into glioblastoma brain tumors. The nanoparticle platform delivers molecules to the tumors that shut down key cancer drivers called brain tumor-initiating cells.

Early phase Northwestern Medicine research published in the journal Proceedings of the National Academy of Sciences has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.

The strategy involves using lipid polymer-based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor-initiating cells (BTICs).

BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy, explained the studys first author, Dou Yu, MD, PhD, research assistant professor of Neurological Surgery.

Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA) short sequences of RNA molecules that reduce the expression of specific cancer-promoting proteins directly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.

This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind, said Yu, who collaborated on the research with principal investigatorMaciej Lesniak, MD, Michael J. Marchese Professor of Neurosurgery and chair of the Department of Neurological Surgery.

Maciej Lesniak, MD, Michael J. Marchese Professor of Neurosurgery and chair of the Department of Neurological Surgery, and Dou Yu, MD, PhD, research assistant professor of Neurological Surgery, were the senior and first authors of the new paper.

Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patients tumor.

In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissues but not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.

This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling, Yu said. Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits.

The strategy could also apply to other medical conditions related to the central nervous system not just brain tumors.

Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform, Yu said.

Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.

Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor-initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer, Lesniak summed up.

Yu and Lesniak, both members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, collaborated on this research with scientists at the Massachusetts Institute of Technology, Harvard University and Northwesterns McCormick School of Engineering.

This study was supported by the National Institutes of Healths National Cancer Institute Outstanding Investigator Award R35CA197725, a Burroughs Wellcome Collaborative Travel Grant, an Elsa U. Pardee Foundation grant, and a Northwestern University I3 Pilot Grant.

Excerpt from:

Nanomedicine Opens Door to Precision Medicine for Brain Tumors - Northwestern University NewsCenter

MU School of Medicine, Indian pharmaceutical company partnering for new holistic medicine treatments – Hannibal.net

Ayurvedic medicine (also called Ayurveda) is one of the worlds oldest medical systems. Originating in India more than 5,000 years ago, this holistic medicine system uses herbal compounds, special diets and other health care practices to augment conventional preventative and disease treatments.

Ayurvedic medicine (also called Ayurveda) is one of the worlds oldest medical systems. Originating in India more than 5,000 years ago, this holistic medicine system uses herbal compounds, special diets and other health care practices to augment conventional preventative and disease treatments.

Now, Kattesh Katti, a researcher at the University of Missouri, has developed a non-toxic delivery method using gold nanoparticles that may revolutionize Ayurveda. His technique for producing the nanoparticles recently was licensed by Dhanvantari Nano Ayushadi (DNA), a company based in Tamil Nadu, India.

Ayurveda uses combinations of chemicals derived from natural herbs, spices, fruits and vegetables in combination with various metals including gold, silver and copper. Together, the chemicals and metals are aimed at treating various disorders. Traditional medicine, such as Ayurveda is used by 65 to 80 percent of the worlds population as their primary form of health care, the World Health Organization estimates.

In the past, metals predominantly used in holistic medicine have been crushed and burned; caregivers grind the ash with herbs to produce an ingestible treatment, said Katti, Curators Distinguished Professor of Radiology and Physics in the MU School of Medicine and the College of Arts and Science and senior research scientist at the University of Missouri Research Reactor (MURR). However, the ways in which those metals are procured often involve mercury; other toxic means to extract the gold or other alloys can be deadly if ingested in the wrong amounts. The gold nanoparticle production methods use a green technology that effectively eliminates the toxicity associated with these treatments.

Katti and his team helped develop green nanotechnologies to produce phytonano medicines, which are compounds that form the basis for Indias Ayurvedic medicine. Scientists mix gold salts with cinnamon and stir the mixture with water to synthesize gold nanoparticles. These green therapies are less toxic to the body and could provide alternatives to current treatments for diseases including cancer, arthritis and diabetes.

The technology is patent pending and Kavita Katti, a senior research scientist at MU Radiology, recently demonstrated the production methods in the DNA labs in India, which has licensed the technology from Katti and the University of Missouri.

These successful production runs within the DNA premises and the efficient training of our personnel fully fulfill the requirements signed in our contract, said Abhaya Kumar Jain, CEO and president of DNA. We look forward to a long-term working and collaborative relationship with Dr. Katti and his team as we collectively advance the field of nano-Ayurvedic medicine to develop the next generation of health care products for the care and treatment of patients across the world.

We are therefore, excited to be the first company in the world to apply principles of green nanotechnology to validate Ayurvedic principles and bring nano-Ayurvedic products to market for the care and savings of human lives suffering from cancer and various diseases/disorders in the world, Jain said.

Research and product development using the green nanotechnology techniques developed in Kattis lab will continue at the facility in India. Using Indian Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy (AYUSH) guidelines, DNA will continue to test formulations that could provide complementary therapies to chemotherapy, radiation and other traditional treatments, Katti said.

We are excited that two great minds, Mr. Abhaya Kumar Jain, a pioneer in the Indian pharmaceutical industry, and Professor Kattesh V Katti, globally recognized as the Father of green nanotechnology, have come together to bring nano-Ayurvedic Medicine technology to India, said Anantkumar Hegde, who is an elected member of the Indian Parliament. This is a marriage made in heaven because India and the world needed the intervention of green nanotechnology for the development of Ayurvedic products through scientifically rigorous methodologies.

The nano-Ayurvedic medicine approaches are built on rigorous scientifically validated methods, Katti said. I am excited to be a part of this important journey using nano-Ayurvedic medicine approaches for treating, healing and curing various diseases. I have always dreamed of helping humanity through my science, I can now see that I am able to use my interdisciplinary green nanotechnology approaches for the development of Ayurvedic products.

During the past five years, companies commercializing MU technologies have secured hundreds of millions of dollars in investments and grants to advance their commercialization efforts. In 2016, the Office of Technology Management and Industry Relations reported that Mizzou received $14.9 million in revenue from more than 40 technology licenses.

Read the original post:

MU School of Medicine, Indian pharmaceutical company partnering for new holistic medicine treatments - Hannibal.net

State can cure skewed disease research – BusinessLIVE – Business Day (registration)

The department wanted nanotechnology to benefit the poor, so it directed funding towards pro-poor initiatives by prioritising research into diseases such as HIV and tuberculosis (TB). However, many less prominent diseases received proportionately more attention. In an unpublished report by the Mapungubwe Institute, researchers found that Parkinsons disease accounts for 2% of nanomedicine research, but is only 0.04% of South African disability-adjusted life years. In addition to Parkinsons, South African scholars study malaria, hepatitis B and Alzheimers in greater proportion than their disability-adjusted life years.

On the other hand, HIV/AIDS is severely understudied. HIV/AIDS accounts for 40% of SAs disability-adjusted life years but represents only 4% of South African nanomedicine research. The gross mismatch between R&D and the needs of South Africans shows that the interests of researchers can be at odds with the needs of the community.

We believe this mismatch is the symptom of global trends in medical R&D and the challenging economics of developing medicines that help the poor. Pharmaceutical companies have little desire to research diseases such as malaria, TB and HIV/AIDS because it will be difficult for them to recoup their R&D costs from medicine sales. In contrast, there is a robust market for cancer and Parkinsons disease medicines and they are, therefore, willing to invest in R&D in these fields.

As a consequence, well-targeted state intervention is needed to encourage R&D on diseases that do not have a market.

In a provocative book titled The Entrepreneurial State, Mariana Mazzucato provides examples of cases in which the state has inevitably been a lead investor and risk-taker in capitalist economies through "mission-oriented" investments and policies.

They include key technologies such as the internet, nanotechnologies, microbiology and drug discovery technologies, where the state played a leading role in achieving the necessary technological breakthroughs.

The state can risk funding initial R&D in areas that have no clear market but that push the bounds of science. An outstanding example is the iPhone all the key technologies behind it, such as the touchscreen, the internet and microprocessors, were funded by the state. The Obama administration also provided a direct $465m loan to Tesla Motors to build its model S.

The state should undertake risky investment to find solutions for its critical medicine research and drug discovery. The focus of private pharma is to focus on less innovative drugs, and private venture capitalists enter only once the real risk has been absorbed by the state.

Bill Gates said the key element to getting a breakthrough is more basic research, and that requires the government to take the lead. Only when that research is pointing towards a product, can we expect the private sector to kick in.

The government should play a leading role as an "entrepreneurial" investor and reap some of the financial rewards over time by retaining ownership of a small proportion of the intellectual property created.

Rather than succumb to its preassigned role as a "market fixer", the governments role should include resource mobilisation and setting the conditions for widespread market commercialisation.

It is time for SA to ask: what is it that the public and private sectors can do together to tackle the dire healthcare situation?

There is a great need for science and politics to combine efforts. A diverse set of governance actors, programmes, instruments and influences are needed by each form of new technology.

These recommendations will not immediately solve all of SAs health problems, but would put the country in a better position to improve its health-innovation system and the wellbeing of its people.

Woodson is assistant professor at Stony Brook University and Perrot is an independent researcher.

Read more:

State can cure skewed disease research - BusinessLIVE - Business Day (registration)

Converging on cancer at the nanoscale – The MIT Tech

This summer, the Koch Institute for Integrative Cancer Research at MIT marks the first anniversary of the launch of the Marble Center for Cancer Nanomedicine, established through a generous gift from Kathy and Curt Marble 63.

Bringing together leading Koch Institute faculty members and their teams, the Marble Center for Cancer Nanomedicine focuses on grand challenges in cancer detection, treatment, and monitoring that can benefit from the emerging biology and physics of the nanoscale.

These challenges include detecting cancer earlier than existing methods allow, harnessing the immune system to fight cancer even as it evolves, using therapeutic insights from cancer biology to design therapies for previously undruggable targets, combining existing drugs for synergistic action, and creating tools for more accurate diagnosis and better surgical intervention.

Koch Institute member Sangeeta N. Bhatia, the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, serves as the inaugural director for the center.

A major goal for research at the Marble Center is to leverage the collaborative culture at the Koch Institute to use nanotechnology to improve cancer diagnosis and care in patients around the world, Bhatia says.

Transforming nanomedicine

The Marble Center joins MITs broader efforts at the forefront of discovery and innovation to solve the urgent global challenge that is cancer. The concept of convergence the blending of the life and physical sciences with engineering is a hallmark of MIT, the founding principle of the Koch Institute, and at the heart of the Marble Centers mission.

The center galvanizes the MIT cancer research community in efforts to use nanomedicine as a translational platform for cancer care, says Tyler Jacks, director of the Koch Institute and a David H. Koch Professor of Biology. Its transformative by applying these emerging technologies to push the boundaries of cancer detection, treatment, and monitoring and translational by promoting their development and application in the clinic.

The centers faculty six prominent MIT professors and Koch Institute members are committed to fighting cancer with nanomedicine through research, education, and collaboration. They are:

Sangeeta Bhatia (director), the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science;

Daniel G. Anderson, the Samuel A. Goldblith Professor of Applied Biology in the Department of Chemical Engineering and the Institute for Medical Engineering and Science;

Angela M. Belcher, the James Mason Crafts Professor in the departments of Biological Engineering and Materials Science and Engineering;

Paula T. Hammond, the David H. Koch Professor of Engineering and head of the Department of Chemical Engineering;

Darrell J. Irvine, professor in the departments of Biological Engineering and Materials Science and Engineering; and

Robert S. Langer, the David H. Koch Institute Professor.

Extending their collaboration within the walls of the Institute, Marble Center members benefit greatly from the support of the Peterson (1957) Nanotechnology Materials Core Facility in the Koch Institutes Robert A. Swanson (1969) Biotechnology Center. The Peterson Facilitys array of technological resources and expertise is unmatched in the United States, and gives members of the center, and of the Koch Institute, a distinct advantage in the development and application of nanoscale materials and technologies.

Looking ahead

The Marble Center has wasted no time getting up to speed in its first year, and has provided support for innovative research projects including theranostic nanoparticles that can both detect and treat cancers, real-time imaging of interactions between cancer and immune cells to better understand response to cancer immunotherapies, and delivery technologies for several powerful RNA-based therapeutics able to engage specific cancer targets with precision.

As part of its efforts to help foster a multifaceted science and engineering research force, the center has provided fellowship support for trainees as well as valuable opportunities for mentorship, scientific exchange, and professional development.

Promotingbroader engagement, the Marble Center serves as a bridge to a wide network of nanomedicine resources, connecting its members to MIT.nano, other nanotechnology researchers, and clinical collaborators across Boston and beyond. The center has also convened a scientific advisory board, whose members hail from leading academic and clinical centers around the country, and will help shape the centers future programs and continued expansion.

As the Marble Center begins another year of collaborations and innovation, there is a new milestone in sight for 2018.Nanomedicine has been selected as the central theme for the Koch Institutes 17th Annual Cancer Research Symposium. Scheduled for June 15, 2018, the event will bring together national leaders in the field, providing an ideal forum for Marble Center members to share the discoveries and advancements made during its sophomore year.

Having next years KI Annual Symposium dedicated to nanomedicine will be a wonderful way to further expose the cancer research community to the power of doing science at the nanoscale, Bhatia says. The interdisciplinary approach has the power to accelerate new ideas at this exciting interface of nanotechnology and medicine.

To learn more about the people and projects of the Koch Institute Marble Center for Cancer Nanomedicine, visit nanomedicine.mit.edu.

Link:

Converging on cancer at the nanoscale - The MIT Tech

Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 – PR Newswire (press release)

LONDON, July 5, 2017 /PRNewswire/ -- "Global Nano Chemotherapy Market & Clinical Trials Outlook 2022" report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.

Download the full report: https://www.reportbuyer.com/product/4884894/

Nano chemotherapy is emerging as an important anti-cancer modality by supplementing the traditional chemotherapy. The main aim of nano chemotherapeutics is to improve the therapeutic efficacy of currently available chemotherapeutic agents by combining it with a nano scale delivery component. The majority of the cancer nanodrugs in the market are liposomes and polymer based nanoformulations which lower the toxicity and enhance the delivery of chemotherapeutics through the passive targeting. It is based on enhanced penetration and retention effect to reduce the lymphatic drainage in tumor tissue.

Conventional chemotherapeutic agents are distributed non-specifically in body where they affect both cancerous and normal cells and thereby it limit the dose availability with in the tumor and also results in suboptimal treatment due to excessive toxicities. To overcome the limitations of chemotherapy treatment, many more therapies has also been emerged.

The use of nanoparticles by both passive and active targeting strategies can enhance the intracellular concentration of drugs in cancer cells while avoiding the toxicity in normal cells. When the nanoparticles bind to a specific receptors and then enter the cell, usually enveloped by endosomes through receptor mediated endocytosis and thereby bypassing the recognition of P glycoprotein.

Nanomedicine has already met with success in oncology domain with various product commercially available in the market. By releasing the efficacy of nanomedicine in oncology, it increases the interest of the market players to commercialize the products in the field of nanotherapeutics and helps to increase the global market. The future of nanotherapeutics is bright and especially for the reversible cross linked nano carriers which are decorated with the cancer targeting ligands and it promote the endocytic uptake in tumor cells. The approach has the potential to overcome the drug resistance which is often with conventional chemotherapies.

For the next generation cancer nanotherapeutics, the complexity is higher which are under clinical development in terms of hybrid structures, surface physiochemical characteristics and mechanisms of delivery and action. There have been rapid advances in the nano therapeutic field in the past decade. Many of the nano carriers have been developed from which some have the great therapeutic potential. However, there remain many challenges in translating the nanoparticle drugs into the clinics. Download the full report: https://www.reportbuyer.com/product/4884894/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-nano-chemotherapy-market--clinical-trials-outlook-2022-300483678.html

Read the rest here:

Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 - PR Newswire (press release)

Metallic nanomolecules could help treat fatal lung disease in the future, notes research – EPM Magazine

New research from Imperial College London, that has recently been published online, examined a novel type of nanoparticle called metal organic frameworks (MOF) as drug carriers for the treatment of pulmonary arterial hypertension (PAH).

Published in Pulmonary Circulation, the research describes the first steps in the development of nanoparticles that can deliver drugs directly to the lungs. The MOFs, created in the laboratory by the researchers, are composed of iron and can expand to create pores within which drugs used to treat PAH can be stored and released where needed.

The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects, explained Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial in a news release. For patients with PAH, it could mean we are able to turn it from a fatal condition, to a chronic manageable one.

When testing the MOFs, the team from Imperial found that the structures reduced inflammation and were not toxic to human lung cells and blood vessels in laboratory conditions. Further testing in rats, showed the MOFs were safe in the animal model over a two-week period with few side-effects a slight build-up of iron was seen in the liver.

One of the biggest limitations in nanomedicine is toxicity, some of the best nanomedicine structures do not make it past the initial stages of development as they kill cells, continued Mitchell. We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells.

The aim is to develop the metallic structures as a drug delivery method where the framework can hold onto the drug and release it under specific conditions, such as a change in pH, temperature or using magnets external to the body to draw the MOFs to the target area. Next steps for this research is to discover the ideal way to get the tiny structures loaded with drugs and delivered to the lungs effectively.

In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung, Mitchell concluded. This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery.

View original post here:

Metallic nanomolecules could help treat fatal lung disease in the future, notes research - EPM Magazine

Nano-sized drug carriers could be the future for patients with lung … – Phys.Org

July 3, 2017 by Ryan O'hare Nanomedicine could help patients with fatal lung conditions. Credit: Imperial College London

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

Scientists based at Imperial College London have tested a new type of nanoparticle called metal organic frameworks (MOF) tiny metal cages less than 100 nanometres across that can be loaded with drug molecules which they believe could potentially be used to treat patients with a devastating condition called pulmonary arterial hypertension (PAH).

In PAH the blood vessels of the lungs constrict and thicken, increasing blood pressure and causing the right side of the heart to work harder and harder, until it eventually fails. The condition is rare but devastating and can affect people of all ages, including babies, young adults and the elderly. Patients in the late stage of the disease have few treatment options beyond transplant, with a mean survival time of around five years following diagnosis.

While there is no cure for PAH, existing treatments work by opening up these blood vessels. These drugs act on blood vessels throughout the body, however, causing blood pressure to drop and resulting in a number of side effects which means the dose at which these drugs can be given is limited.

In their latest study, published online in Pulmonary Circulation, the multidisciplinary group at Imperial describes how it has taken the first in a number of steps to develop nanoparticles which could deliver drugs directly to the lungs, showing that the basic structures are not harmful to cells.

Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial, who led the research, said: "The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects. For patients with pulmonary arterial hypertension, it could mean we are able to turn it from a fatal condition, to a chronic manageable one."

Metallic cages for drug delivery

The tiny metallic structures composed of iron were made in the lab of Professor Paul Lickiss and Dr Rob Davies's, from the Department of Chemistry and by Dr Nura Mohamed during her PhD studies at Imperial. Dr Mohamed, who was funded by the Qatar Foundation, made the structures so existing drugs used to treat PAH could fit inside them.

These structures were tested in human lung cells and blood vessel cells, which were grown from stem cells in the blood of patients with PAH. The team found that the structures reduced inflammation and were not toxic to the cells.

Further tests showed that the MOFs were safe in rats, with animals injected with MOFs over a two-week period showing few side effects other than a slight build-up of iron in the liver.

"One of the biggest limitations in nanomedicine is toxicity, some of best nanomedicine structures do not make it past the initial stages of development as they kill cells," said Professor Mitchell. "We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells."

MOFs are an area of interest in nanomedicine, with engineers aiming to develop them as carriers which can hold onto drug cargo, releasing it under specific conditions, such as changes in pH, temperature, or even when the nanostructures are drawn to the target area by magnets outside the body.

Beyond the finding that their iron nanostructures were non-toxic, the team believes the MOFs may have additional therapeutic properties. There was evidence to suggest anti-inflammatory properties, with the MOFs reducing the levels of an inflammatory marker in the blood vessels, called endothelin-1, which causes arteries to constrict. In addition, iron is also a contrast agent, meaning it would show up on scans of the lungs to show where the drug had reached.

The MOFs have not yet been tested in patients, but the next step is to load the tiny metallic structures with drugs and work out the best way to get them to target their cargo to the lungs. The researchers are confident that if successful, the approach could move to trials for patients, with a drug candidate ready to test within the next five years. The MOFs could potentially be delivered by an inhaler into the lung, or administered by injection.

"In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung," explained Professor Mitchell. "This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery."

Explore further: Longer-lasting pain relief with MOFs

More information: Nura A. Mohamed et al. Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy, Pulmonary Circulation (2017). DOI: 10.1177/2045893217710224

To treat headaches, back pain or fever, most of us have reached for ibuprofen at one point or another. But we often have to take doses every four to six hours if the pain warrants it. Now scientists are working on a way to ...

People with a lung scarring condition that leaves them fighting for breath could be helped by a new medication, research suggests.

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for ...

(HealthDay)Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant.

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary ...

(Medical Xpress) -- Scientists at UCD have identified a potential new treatment for life-threatening complications associated with chronic obstructive lung diseases like emphysema and chronic bronchitis. Chronic obstructive ...

(Phys.org)One of the most promising microscale power sources for portable and wearable electronics is a micro-supercapacitorthey can be made thin, lightweight, highly flexible, and with a high power density. Normally, ...

An international research team that includes University of Central Florida Professor Enrique del Barco, Damien Thompson of the University of Limerick and Christian A. Nijhuis of the National University of Singapore has cracked ...

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

The possibility of looking inside silicon chips to see their tiny working parts, without damaging the chips, is a step closer thanks to an international team led by scientists at the LCN.

Science fiction is full of fanciful devices that allow light to interact forcefully with matter, from light sabers to photon-drive rockets. In recent years, science has begun to catch up; some results hint at interesting ...

Dialysis, in the most general sense, is the process by which molecules filter out of one solution, by diffusing through a membrane, into a more dilute solution. Outside of hemodialysis, which removes waste from blood, scientists ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:

Nano-sized drug carriers could be the future for patients with lung ... - Phys.Org

Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics – Medical Xpress

June 30, 2017 Size switchable nano-theranostics constructed with decomposable inorganic nanomaterials for acidic TME targeted cancer therapy. (a) A scheme showing the preparation of HSA-MnO2-Ce6&Pt (HMCP) nanoparticles, and (b) their tumor microenvironment responsive dissociation to enable efficient intra-tumoral penetration of therapeutic albumin complexes. (c) A scheme showing the preparation of Ce6(Mn)@CaCO3-PEG, and (d) its acidic TME responsive dissociation for enhanced MR imaging and synergistic cancer therapy. Credit: Science China Press

Cancer is one of leading causes of human mortality around the world. The current mainstream cancer treatment modalities (e.g. surgery, chemotherapy and radiotherapy) only show limited treatment outcomes, partly owing to the complexities and heterogeneity of tumor biology. In recent decades, with the rapid advance of nanotechnology, nanomedicine has attracted increasing attention as promising for personalized medicine to enable more efficient and reliable cancer diagnosis and treatment.

Unlike normal cells energized via oxidative phosphorylation, tumor cells utilize the energy produced from oxygen-independent glycolysis for survival by adapting to insufficient tumor oxygen supply resulting from the heterogeneously distributed tumor vasculatures (also known as the Warburg effect). Via such oncogenic metabolism, tumor cells would produce a large amount of lactate along with excess protons and carbon dioxide, which collectively contribute to enhanced acidification of the extracellular TME with pH, often in the range of 6.5 to 6.8, leading to increased tumor metastasis and treatment resistance.

With rapid advances in nanotechnology, several catalogs of nanomaterials have been widely explored for the design of cancer-targeted nano-theranostics. In a new overview published in the Beijing-based National Science Review, co-authors Liangzhu Feng, Ziliang Dong, Danlei Tao, Yicheng Zhang and Zhuang Liu at the Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University in Suzhou, China present new developments in the design of novel multifunctional nano-theranostics for precision cancer nanomedicine by targeting the acidic TME and outline the potential development directions of future acidic tumor microenvironment-responsive nano-theranostics.

"Various types of pH-responsive nanoprobes have been developed to enable great signal amplification under slightly reduced pH within solid tumors. By taking the acidic TME as the target, smart imaging nanoprobes with excellent pH-responsive signal amplification would be promising to enable more sensitive and accurate tumor diagnosis," they state in the published study.

"As far as nano-therapeutics are concerned, it has been found that the acidic TME responsive surface charge reverse, PEG corona detachment and size shrinkage (or decomposition) of nanoparticles would facilitate the efficient tumor accumulation, intra-tumoral diffusion and tumor cellular uptake of therapeutics, leading to significantly improved cancer treatment. Therefore, the rational development of novel cancer-targeted nano-theranostics with sequential patterns of size switch from large to small, and surface charge reverse from neutral or slightly negative to positive within the tumor, would be more preferred for efficient tumor-targeted drug delivery."

The scientists also write, "For the translation of those interesting smart pH-responsive nano-therapeutics from bench to bedside, the formulation of those nanoscale systems should be relatively simple, reliable and with great biocompatibility, since many of those currently developed nano-theranostics were may be too complicated for clinical translation."

Explore further: Treatment with Alk5 inhibitor improves tumor uptake of imaging agents

More information: Liangzhu Feng et al, The acidic tumor microenvironment: a target for smart cancer nano-theranostics, National Science Review (2017). DOI: 10.1093/nsr/nwx062

A form of genetic variation, called differential RNA splicing, may have a role in tumor aggressiveness and drug resistance in African American men with prostate cancer. Researchers at the George Washington University (GW) ...

While mutations in protein-coding genes have held the limelight in cancer genomics, those in the noncoding genome (home to the regulatory elements that control gene activity) may also have powerful roles in driving tumor ...

A molecular test can pinpoint which patients will have a very low risk of death from breast cancer even 20 years after diagnosis and tumor removal, according to a new clinical study led by UC San Francisco in collaboration ...

Scientists have had limited success at identifying specific inherited genes associated with prostate cancer, despite the fact that it is one of the most common non-skin cancers among men. Researchers at University of Utah ...

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

Follicular lymphoma is an incurable cancer that affects over 200,000 people worldwide every year. A form of non-Hodgkin lymphoma, follicular lymphoma develops when the body starts making abnormal B-cells, which are white ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to see the original:

Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics - Medical Xpress

Colon cancer nuclear pore dynamics are captured by HS-AFM – Phys.Org

June 30, 2017 Utilization of HS-AFM enabled observation and video-imaging of structure and dynamics of FG-Nups filament, a protein complex of soft and flexible lining. The figure shows the original image of FG-Nups filament and that after processing by Fast Fourier Transform (FFT) and a bandpass-filter (a bandpass-filter allows permeation of certain wavelength light only). Credit: Kanazawa University

One of the key reasons for cancer mortality is the highly invasive behaviour of cancer cells, which is often due to aggressive metastasis. Metastasis is facilitated by various growth factors and cytokines secreted from cells of the immune system, which operate through various signaling pathways. Remarkably, these signaling pathways enter the nucleus through the nuclear pore complex (NPC), which is supposed to act as a doorkeeper to the nucleus. NPC is, in fact, a nanomachine consisting of multiple copies of about 30 different proteins, collectively called nucleoporin.

Although small molecules are able to go through the nuclear pores rather freely, molecules larger than 40 kDa could do so effectively only by binding to specific transporter proteins that interact with FG-Nups (nucleoporins have repeating units of two amino acids phenylalanine (F) and glycine (G), which are the tentacle proteins having specific and selecting roles in pore transportation. Although different models are proposed, how FG-Nups participates in the nucleus-cytoplasm transport remains largely unknown. Nonetheless, the concomitant assessment of nanoscopic structures and dynamics has been technically unfeasible, a situation prevailing throughout cell biology research. The direct visualization of NPC dynamics at nanoscale resolution was thought to be impossible.

The research team of Kanazawa University investigated this important issue and obtained the groundbreaking results by combined high-resolution live cell imaging, electron microscopy, and high-speed AFM (HS-AFM) which is developed by themselves to investigate the native nanoscopic spatial and temporal dynamics in NPC structures in the colon cancer cells.

First, they generated NPC stable cell lines expressing GFP (green fluorescent protein) and confirmed by fluorescent microscopy. Next, they isolated the highly purified nuclear envelope which was confirmed by the use of negative stain electron microscopy and confocal microscopy. Then, they started the observation of spatiotemporal changes at millisecond and nanometer scale of native state NPC structure in colon cancer cells by combining high resolution live cell imaging and electron microscopy. Notably, they performed the observation of living nuclear envelope and nuclear pores using HS-AFM.

The research team of Kanazawa University was, indeed, successful in imaging the dynamics of NPC proteins in cancer cells, which are the building blocks of the nuclear pore (Figure 1). MLN8237/alisertib, an apoptotic and autophagic inducer, is currently undergoing several cancer clinical trials. This drug was reported to inhibit nucleoporin expression and activities. The researchers visualized native and drug-treated FG-Nups by HS-AFM. In particular, the extended and retracted FG-Nups having a spider cobweb appearance were lost in drug-treated samples (Figure 2). The research team concluded that via HS-AFM, they visualized the deformation and loss of FG-Nups nuclear pore barrier, which might be the first nano dying code discovered in the world.

The present study by the research team of Kanazawa University enabled visualization of structure and dynamics of the nuclear membrane pore at nanometer scale, and it is shown that deformation and loss of the nuclear membrane pore barrier would be one of the dying codes of cancer cells. These findings stand for a new paradigm in our understanding of nuclear transport, which has, up to this point, remained an enigmatic problem throughout the nano-medicine and cell biology field. Current findings are based on the crowning bio-imaging technology developed at Kanazawa University. This study has medical applications including acting as a novel "nano-endoscopy" to visualize intra-cellular organelles such as the nucleus and nuclear pores, and molecular dynamics in cancer cells and other diseases.

Explore further: AFM films 'living' nuclear pore complexes at work for the first time

More information: Mahmoud Shaaban Mohamed et al, High-Speed Atomic Force Microscopy Reveals Loss of Nuclear Pore Resilience as a Dying Code in Colorectal Cancer Cells, ACS Nano (2017). DOI: 10.1021/acsnano.7b00906

Journal reference: ACS Nano

Provided by: Kanazawa University

Using an ultra fast-scanning atomic force microscope, a team of researchers from the University of Basel has filmed "living" nuclear pore complexes at work for the first time. Nuclear pores are molecular machines that control ...

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have uncovered new clues to how a molecular machine inside the cell acts as a gatekeeper, allowing some molecules to enter ...

The transportation of certain molecules into and out of the cell nucleus takes place via nuclear pores. For some time, detailed research has been conducted into how these pores embedded in the nuclear envelope are structured. ...

It was a 3D puzzle with over 1000 pieces, with only a rather fuzzy outline as a guide. But scientists at EMBL have now put enough pieces in place to see the big picture. In a study published today in Science, they present ...

A team led by Naoko Imamoto of the RIKEN Advanced Science Institute in Wako, Japan, has uncovered processes governing the formation of functionally important structures called nuclear pore complexes (NPCs) in dividing human ...

(Phys.org)Two teams of researchers taking different approaches have successfully mapped and diagramed the nuclear pore complex (NPC)protein complexes that make up the pores in the nuclear envelope that allow or prevent ...

Science fiction is full of fanciful devices that allow light to interact forcefully with matter, from light sabers to photon-drive rockets. In recent years, science has begun to catch up; some results hint at interesting ...

Dialysis, in the most general sense, is the process by which molecules filter out of one solution, by diffusing through a membrane, into a more dilute solution. Outside of hemodialysis, which removes waste from blood, scientists ...

Rice University scientists have fabricated a durable catalyst for high-performance fuel cells by attaching single ruthenium atoms to graphene.

Researchers from TU Delft in The Netherlands, in collaboration with a team at the University of Cambridge (U.K.), have found a way to create and clean tiny mechanical sensors in a scalable manner. They created these sensors ...

Sensitive sensors must be isolated from their environment as much as possible to avoid disturbances. Scientists at ETH Zurich have now demonstrated how to remove from and add elementary charges to a nanosphere that can be ...

Engineers at Caltech have for the first time developed a light detector that combines two disparate technologiesnanophotonics, which manipulates light at the nanoscale, and thermoelectrics, which translates temperature ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:

Colon cancer nuclear pore dynamics are captured by HS-AFM - Phys.Org

Neuron-integrated nanotubes to repair nerve fibers – Phys.org – Phys.Org

June 27, 2017 Scientists have proven that these nanomaterials may regulate the formation of synapses, specialized structures through which the nerve cells communicate, and modulate biological mechanisms, such as the growth of neurons, as part of a self-regulating process. Credit: Pixabay

Carbon nanotubes exhibit interesting characteristics rendering them particularly suited to the construction of special hybrid devices consisting of biological issue and synthetic material. These could re-establish connections between nerve cells at the spinal level that were lost due to lesions or trauma. This is the result of research published in the scientific journal Nanomedicine: Nanotechnology, Biology, and Medicine conducted by a multi-disciplinary team comprising SISSA (International School for Advanced Studies), the University of Trieste, ELETTRA Sincrotrone and two Spanish institutions, Basque Foundation for Science and CIC BiomaGUNE.

Researchers have investigated the possible effects on neurons of interactions with carbon nanotubes. Scientists have proven that these nanomaterials may regulate the formation of synapses, specialized structures through which the nerve cells communicate, and modulate biological mechanisms such as the growth of neurons as part of a self-regulating process. This result, which shows the extent to which the integration between nerve cells and these synthetic structures is stable and efficient, highlights possible uses of carbon nanotubes as facilitators of neuronal regeneration or to create a kind of artificial bridge between groups of neurons whose connection has been interrupted. In vivo testing has already begun.

"Interface systems, or, more generally, neuronal prostheses, that enable an effective re-establishment of these connections are under active investigation," says Laura Ballerini (SISSA). "The perfect material to build these neural interfaces does not exist, yet the carbon nanotubes we are working on have already proved to have great potentialities. After all, nanomaterials currently represent our best hope for developing innovative strategies in the treatment of spinal cord injuries." These nanomaterials are used both as scaffolds, as supportive frameworks for nerve cells, and as interfaces transmitting those signals by which nerve cells communicate with each other.

Many aspects, however, still need to be addressed. Among them, the impact on neuronal physiology of the integration of these nanometric structures with the cell membrane. "Studying the interaction between these two elements is crucial, as it might also lead to some undesired effects, which we ought to exclude," says Laura Ballerini. "If, for example, the mere contact provoked a vertiginous rise in the number of synapses, these materials would be essentially unusable."

"This," Maurizio Prato adds, "is precisely what we have investigated in this study where we used pure carbon nanotubes."

The results of the research are extremely encouraging: "First of all, we have proved that nanotubes do not interfere with the composition of lipids, of cholesterol in particular, which make up the cellular membrane in neurons. Membrane lipids play a very important role in the transmission of signals through the synapses. Nanotubes do not seem to influence this process, which is very important."

The research has also highlighted the fact that the nerve cells growing on the substratum of nanotubes via this interaction develop and reach maturity very quickly, eventually reaching a condition of biological homeostasis. "Nanotubes facilitate the full growth of neurons and the formation of new synapses. This growth, however, is not indiscriminate and unlimited. We proved that after a few weeks, a physiological balance is attained. Having established the fact that this interaction is stable and efficient is an aspect of fundamental importance."

Laura Ballerini says, "We are proving that carbon nanotubes perform excellently in terms of duration, adaptability and mechanical compatibility with the tissue. Now, we know that their interaction with the biological material, too, is efficient. Based on this evidence, we are already studying the in vivo application, and preliminary results appear to be quite promising also in terms of recovery of the lost neurological functions."

Explore further: A 'bridge' of carbon between nerve tissues

More information: Niccol Paolo Pampaloni et al, Sculpting neurotransmission during synaptic development by 2D nanostructured interfaces, Nanomedicine: Nanotechnology, Biology and Medicine (2017). DOI: 10.1016/j.nano.2017.01.020

A new material made of carbon nanotubes supports the growth of nerve fibers, bridging segregated neural explants and providing a functional re-connection. The study, which was coordinated by SISSA in Trieste, also observed ...

A nanomaterial engineered by researchers at Duke can help regulate chloride levels in nerve cells that contribute to chronic pain, epilepsy, and traumatic brain injury.

Research done by scientists in Italy and Switzerland has shown that carbon nanotubes may be the ideal "smart" brain material. Their results, published December 21 in the advance online edition of the journal Nature Nanotechnology, ...

Nanotubes can be used for many things: electrical circuits, batteries, innovative fabrics and more. Scientists have noted, however, that nanotubes, whose structures appear similar, can actually exhibit different properties, ...

Innovative graphene technology to buffer the activity of synapses this is the idea behind a recently-published study in the journal ACS Nano coordinated by the International School for Advanced Studies in Trieste (SISSA) ...

Using photoluminescent probes, researchers have devised a sensitive and selective way of detecting carbon nanotubes. Innovations in energy and electronics, together with traditional reinforcement composite products, will ...

Building transient electronics is usually about doing something to make them stop working: blast them with light, soak them with acid, dunk them in water.

Researchers have developed a novel platform to more accurately detect and identify the presence and severity of peanut allergies, without directly exposing patients to the allergen, according to a new study published in the ...

Scientists have found a way to make carbon both very hard and very stretchy by heating it under high pressure. This "compressed glassy carbon", developed by researchers in China and the US, is also lightweight and could potentially ...

After radiation treatment, dying cancer cells spit out mutated proteins into the body. Scientists now know that the immune system can detect these proteins and kill cancer in other parts of the body using these protein markers ...

Nanotechnology is creating new opportunities for fighting disease from delivering drugs in smart packaging to nanobots powered by the world's tiniest engines.

Biomedical engineers have built simple machines out of DNA, consisting of arrays whose units switch reversibly between two different shapes.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

The rest is here:

Neuron-integrated nanotubes to repair nerve fibers - Phys.org - Phys.Org